Trial Patient Dies From a Stemline SL-401 Side Effect

A trial patient died from a Stemline Therapeutics' SL-401 cancer drug side effect, the family confirmed. Not reported by Stemline (STML) - Get Report , the death came a day prior to a $45 million stock offering on Jan. 19. The patient's family confirmed that the BPDCN cancer patient died due to capillary leak syndrome. Despite increased safety monitoring and new dosing rules, this is the third death from the same side effect. Hoping to use the phase II study as the basis for its marketing application to the FDA, Stemline cannot afford a serious setback. 

This article was written by a staff member of TheStreet.